INT232414

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 3.28
Pain Relevance 2.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
enterocyte 1
ganglia 1
Ifx (Mus musculus)
Pain Link Frequency Relevance Heat
Infliximab 239 100.00 Very High Very High Very High
Etanercept 72 100.00 Very High Very High Very High
rheumatoid arthritis 90 99.60 Very High Very High Very High
antagonist 54 99.02 Very High Very High Very High
cytokine 24 95.68 Very High Very High Very High
monoamine 1 88.72 High High
Adalimumab 101 87.56 High High
COX2 26 82.24 Quite High
Inflammation 12 81.60 Quite High
diclofenac 17 81.04 Quite High
Disease Link Frequency Relevance Heat
Cold Sores 89 100.00 Very High Very High Very High
Apoptosis 48 100.00 Very High Very High Very High
Rheumatoid Arthritis 91 99.60 Very High Very High Very High
Colitis 36 96.44 Very High Very High Very High
Disease 68 92.52 High High
Infection 20 85.04 High High
INFLAMMATION 17 81.60 Quite High
Stress 2 74.40 Quite High
Low Back Pain 58 70.56 Quite High
Necrosis 11 58.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Two recent independent reports confirmed that IE regions of latent HSV-1 are repressed, at least in part, through the deposition of facultative heterochromatin (indicated by triMeH3K27 enrichment) on the IE promoters and this deposition is regulated by LAT [26], [27] and an additional report has also proven that the inhibition of the histone demethylase LSD-1 using monoamine oxidase inhibitors results in the recruitment of repressive histone marks and has the capability of blocking HSV-1 lytic replication and reactivation from latency in vitro and in explanted ganglia [28].
Negative_regulation (repressed) of HSV-1 in ganglia associated with cold sores and monoamine
1) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2973973 Disease Relevance 0.80 Pain Relevance 0.04
Fourthly, data on cost-effectiveness of IFX in early RA are missing, which is a major concern considering the cost of this medication and current limitations in health care resources.
Negative_regulation (effectiveness) of IFX associated with infliximab and rheumatoid arthritis
2) Confidence 0.26 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376089 Disease Relevance 0.80 Pain Relevance 0.61
All three subgroups experienced improvements from baseline in both TJC and SJC at all time points measured, with those who reported intolerance to IFX or loss of response achieving a slightly greater benefit compared with those who had no response to IFX (TableĀ 3).
Negative_regulation (loss) of IFX associated with infliximab
3) Confidence 0.17 Published 2008 Journal Clin Rheumatol Section Body Doc Link PMC2468311 Disease Relevance 0.05 Pain Relevance 0.24
Both anti-TNF strategies, IFX and ETC, were equally effective in suppressing enterocyte apoptosis, most likely by inactivation of circulating TNF-?.



Negative_regulation (inactivation) of IFX in enterocyte associated with infliximab, apoptosis and etanercept
4) Confidence 0.14 Published 2008 Journal International Journal of Medical Sciences Section Abstract Doc Link PMC2452978 Disease Relevance 1.17 Pain Relevance 0.48
(1 or 10 ng/mL) was significantly reduced by its blocker IFX (10 ?
Negative_regulation (blocker) of IFX associated with infliximab
5) Confidence 0.07 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875629 Disease Relevance 0.16 Pain Relevance 0.31
For patients who had prior exposure to TNF antagonists, study investigators documented the reasons for discontinuation of IFX and/or ETN in four prespecified categories: never achieved response (lack of response), loss of initial response (loss of response), adverse effects (intolerance), and other.
Negative_regulation (discontinuation) of IFX associated with infliximab, antagonist and etanercept
6) Confidence 0.06 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911911 Disease Relevance 0.30 Pain Relevance 0.58

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox